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Abstract 
Cutaneous plasmacytosis is a rare condition affecting middle-aged individuals, 
characterized by multiple red-brown papules and plaques over the trunk. It has been 
reported mainly in Japan. The condition is accompanied by polyclonal 
hypergammaglobulinemia and superficial lymphadenopathy. Lung or retroperitoneal 
involvement occurs rarely. In the present study, three consecutive cases of cutaneous 
plasmacytosis were observed histologically to have abundant infiltration of 
IgG4-bearing plasma cells. All three were associated with superficial lymphadenopathy, 
one with interstitial lung involvement showing ground-glass opacity on CT and the 
others with bone marrow plasmacytosis, showing histological evidence of an increased 
number of IgG4-positive plasma cells. All three had polyclonal 
hypergammaglobulinemia, one had high serum concentration of IgG4, and all had 
elevated serum IL-6. The ratios of IgG4+ to IgG+ plasma cells were assessed using skin 
biopsy specimens with pemphigus (n=7), discoid lupus erythematosus (n=5) and 
morphea (n=2) (mean ratios; 19%, 0%, and 0%, respectively); we noted the proportion of 
IgG4-positive plasma cells in cutaneous plasmacytosis (mean: 48%).  
IgG4-related sclerosing disease is a newly recognized systemic disorder characterized 
by lymphoplasmacytic infiltration and fibrosis, and by a high serum IgG4 level and 
increased IgG4-positive plasma cells in the tissues. Skin manifestations of this disorder 
have not been described. Although cutaneous plasmacytosis could be a chronic allergic 
hypersensitivity reaction, our findings raise the possibility of a relationship in 
pathogenesis between cutaneous plasmacytosis and IgG4-related sclerosing disease.   
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Introduction 
Cutaneous plasmacytosis is a rare skin disorder of unknown etiology. It manifests as 
brown to red papules containing polyclonal plasma cells, predominantly on the trunk. 1-3  
This condition has been recognized principally in Asian patients, with a few cases in 
Caucasians.4-7 The condition is accompanied by polyclonal hypergammaglobulinemia 
and superficial lymphadenopathy. Histology shows a dense perivascular and 
periadnexal infiltrate composed almost entirely of polyclonal plasma cells.  
Patients with cutaneous plasmacytosis often have systemic manifestations, including 
anemia, fever, hepatosplenomegaly and superficial lymphadenopathy. 
Lymphadenopathy occurs in more than 50% of patients.8-10 The lung,10-12 breast4 and 
retroperitoneum13 are involved less frequently. In the lung, cutaneous plasmacytosis 
may present as lymphoid interstitial pneumonia10 or as multiple tiny nodules.11 In such 
cases, some investigators have called the disorder systemic plasmacytosis.14 Most cases 
have followed a chronic and benign clinical course over a decade without spontaneous 
remission, suggesting that the condition is a benign reactive proliferation of plasma 
cells1,9. A few cases have followed an aggressive clinical course as lymphoma15, lymphoid 
interstitial pneumonia10, or renal failure8,9. Treatment has included topical and 
systemic corticosteroids16, cyclophosphamide4, topical tacrolimus,17 PUVA and other 
chemotherapy.6,9,18,19,20  
Recent studies have shown that sclerosing pancreatitis is a unique immunoglobulin (Ig) 
G4-related disease.21 Many IgG4-positive plasma cells are present in extrapancreatic 
organs in patients with sclerosing pancreatitis, and IgG4-related systemic disorder has 
been proposed as a distinct disease entity.22 Four subclasses of IgG have been defined 
from the antigenic uniqueness of their heavy chains. The subclasses are designated 
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IgG1, IgG2, IgG3 and IgG4, in order of their serum concentrations, which are 
respectively ~60, 25, 10 and 5%. Each IgG subclass expresses a unique profile of effector 
activities. The IgG4 subclass, which is known to have poor complement- and 
leucocyte-activating properties, may be characteristic of chronic antigen stimulation.23 
Sclerosing pancreatitis is manifest as multifocal fibrosclerosis,24 which in turn shows as 
various combinations of the following conditions: orbital pseudotumor,25 sclerosing 
sialoadenitis,26 hepatic inflammatory pseudotumor, sclerosing cholangitis,27 
mediastinal and retroperitoneal fibrosis,28,29 inflammatory aortic aneurysm30, lymphoid 
interstitial pneumonia31 or inflammatory pseudotumor of the lung,32 
lymphadenopathy,29,33 tubulointerstitial nephritis,34 and hypophysitis.35 Histological 
findings are similar in these diseases, and there is marked lymphoplasmacytic 
infiltration with sclerosis, obliterative phlebitis and occasional eosinophils. Serum 
assay for IgG4 is useful for diagnosis, and abundant IgG4-bearing plasma cells found 
histologically are a hallmark of these diseases. 24  
No cutaneous manifestations of multifocal fibrosclerosis and/or autoimmune 
pancreatitis have been reported. IgG4-bearing plasma cells were assessed on skin 
biopsy specimens in these patients in order to investigate the association with 
IgG4-related systemic disorder, since cutaneous plasmacytosis is likely to be a skin 
manifestation of systemic disorder. Since autoantibodies belong mainly to the IgG4 
and IgG1 subclasses in pemphigus,23 the controls were pemphigus (n=7), discoid lupus 
erythematosus (n=5) and morphea (n=2).  
 
 6 
Material and Methods 
Skin and serum samples were obtained from three patients having cutaneous 
plasmacytosis; two were treated at Kyoto University Hospital and the third at the 
Dermatology Department of Osaka University Hospital. We examined various tissues, 
including lymph node, lung, and bone marrow.  
We also obtained skin biopsies from 7 patients with pemphigus (pemphigus vulgaris, 
n=4; pemphigus foliaseus, n=3), 5 with discoid lupus erythematosus, and two with 
morphea, taken from the database of the Department of Diagnostic Pathology, Kyoto 
University Hospital; they were used as controls in IgG4 immunohistochemistry. Control 
subjects were included in this study according to the following criteria for pemphigus: (i) 
the clinical presence of intraepidermal blisters; (ii) the presence of squamous epithelial 
intercellular deposition of IgG and/or C3 according to direct immunofluorescence 
studies; (iii) the presence of antibodies against desmosomal cadherins desmoglein (Dsg) 
1 for pemphigus foliaceus and/or Dsg 3 for pemphigus vulgaris on Enzyme-Linked 
ImmunoSorbent Assay; and (iv) histological findings consistent with pemphigus 
foliaceus: subcorneal blister with acantholytic keratinocytes and pemphigus vulgaris; 
suprabasal acantholysis with blister formation.36 For discoid lupus erythematosus we 
required: (i) the presence of a well-demarcated red-purple macule or papule with a 
superficial scale; (ii) histological evidence of vacuolar interface dermatitis with dense 
perivascular, interstitial, and periadnexal inflammation, with occasional basement 
membrane thickening and dermal mucin deposition; or (iii) positive lupus band test.37 
For morphea (localized scleroderma), we required: (i) the thickening and fibrosis to be 
limited clinically to the skin; and (ii) histological findings of thickening and sclerosis of 
the reticular dermis, with increased width of collagen bundles, and a superficial and 
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deep perivascular lymphocytic infiltrate containing plasma cells.38 
All biopsy specimens were fixed in neutral buffered formalin, embedded in paraffin, and 
sliced into sections 4 μm thick. Morphological characteristics were assessed on standard 
HE sections. Immunohistochemistry was performed using an autoimmunostainer 
(Ventana XT System Benchmark; Ventana Medical System, Inc., Tucson, AZ, USA). The 
following antibodies were applied: anti-IgG (polyclonal; Ventana), IgG4 (1:500, clone 
HP6025; Serotec, Oxford, UK), IgA (polyclonal; Ventana), IgM (polyclonal; Ventana), 
CD3 (2GV6; Ventana), CD20 (1:1000, L26; DakoCytomation, Denmark), CD79a (1:400, 
JCB117; DakoCytomation), and immunoglobulin κ and λ-light chins (polyclonal; 
Ventana). The number of IgG+ and IgG4+ plasma cells at three different high power 
fields (HPF) was counted in each section, and an average number of positive cells per 
HPF was calculated. The percentage of IgG4+/IgG+ plasma cells was determined.33 
To compare continuous variables we used the unpaired Student t test or 
Mann-Whitney’s U test. Statistical analysis was performed using StataSE 9.0 (Stata 





Table 1 lists the clinical characteristics of patients with cutaneous plasmacytosis. All 
three were men, aged 54, 55 and 61 years. One case has been reported previously in 
detail.17 All three patients came to our attention because of multiple reddish-brown 
papules over the trunk and face, which persisted for 5 (Pt 1), 3 (Pt 2) and 1.5 (Pt 3) years, 
respectively; see Fig. 1A. Their general conditions were relatively good, except that one 
had fatigue and one other had night sweat. All exhibited superficial lymphadenopathy. 
CT revealed diffuse lymphadenopathy, involving cervical, parotid, axillary, 
para-extrailiac, and inguinal locations. Chest CT revealed ground glass attenuation, 
with a slight reticular shadow in the middle and lower lobe bilaterally in one patient 
(Fig.1B). No honeycombing was noted. No fever or hepatosplenomegaly was found in 
any patient. All patients denied sicca syndrome and weight loss.  
 
Laboratory test results were as follows. Blood cell count with differential was normal. 
The erythrocyte sedimentation rate was raised in two of the patients tested (116 mm/h 
(Pt 1), 44 mm/h (Pt 3), normal 2-10 mm/h). C-reactive protein was raised in all three 
patients (2.1 mg/dL (Pt 1), 12.9 mg/dL (Pt 2), and 0.6 mg/dL (Pt 3); normal is <0.2 
mg/dL). Total serum protein was elevated, and serum protein electrophoresis revealed 
polyclonal hypergammaglobulinemia with IgG (4637 mg/dL (Pt 1), 6480 mg/dL (Pt 2), 
and 2624 mg/dL (Pt 3); normal is 826-1840 mg/dL), IgA (475 mg/dL (Pt 1), 480 mg/dL (Pt 
2), and 332 mg/dL (Pt 3); normal is 93-426 mg/dL) and IgM (112 mg/dL (Pt1), 325 mg/dL 
(Pt 2), and 80 mg/dL (Pt 3); normal is 27-205 mg/dL). One of the patients had an 
elevated serum IgG4 of 610 mg/dL (13.2% of total IgG, normal 4.8-105 mg/dL) and a 
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high serum IgE of 2600 IU/mL (normal 27.5-138.3 IU/mL). Serum interleukin (IL)-6 
level was raised (6.9 pg/mL (Pt 1), 74.5 pg/mL (Pt 2), and 4.6 pg/mL (Pt 3); normal is 
<4.0 pg/mL). Antinuclear antibody was positive in one patient (1:40). There was no 
measurable Bence-Jones protein in the urine. Flow cytometric evaluation on a lymph 
node in one patient revealed a polytypic lymphoplasmacytic infiltrate based on cell 
marker analysis. 
 
Predonisolone at low dosage (15 mg/day, 0.25 mg/kg) was started for cutaneous lesions 
in two patients, and tacrolimus ointment for the third. The third patient had severe 
plaques particularly on the face. Therefore, the tacrolimus ointment was applied to 
facial lesions. All patients were well at follow-up from 3 months to 3 years (Table 1). The 
treatment reduced the erythema and induration of the facial lesions for the third 
patient after 3 months. Therapeutic intervention via oral steroid had little effect in 
other two patients, and –although not complete- a reduction in size of the skin lesions 
was observed. There was clinical response to predonisolone, with diminuation in size of 
lymph nodes and symptomatic improvement.  
 
Pathological findings 
Biopsy specimens of a papule on the trunk showed a moderately dense superficial and 
deep perivascular and periadnexal infiltrate, composed largely of plasma cells without 
atypia (Fig. 1C, 2A). None of the cases showed obliterative phlebitis or other vascular 
changes, or dermal sclerosis. An immunohistochemical study found that the infiltrating 
plasma cells were positive for IgG, IgA, IgM, κ, and λ-chains. There was no light chain 
restriction. A diagnosis of plasmacytosis was made. The number of IgG4+ plasma cells 
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was elevated (53 per HPF (Pt 1), 62 per HPF (Pt 2), and 72 per HPF (Pt 3)); see Figs. 2B, 
C. The proportion of IgG4+/IgG+ plasma cells was 42.2 % (Pt 1), 43.7% (Pt 2), and 
58.1 % (Pt 3); see Table 2.  
Histology, obtained by transbronchial lung biopsy from segment 4 of the right lobe, 
showed thickening of the alveolar septum with marked infiltration of lymphoplamacytic 
cells, consistent with lymphocytic interstitial pneumonia (Fig. 1D). IgG4+ plasma cells 
were slightly increased in the interstitium (IgG4+/IgG+ plasma cells 15.4%).  
 
Lymph nodes from all three patients demonstrated interfollicular expansion, with 
variable sized follicles. The lymph node architecture was well preserved. The reactive 
follicle comprised a germinal center surrounded by a discrete mantle zone. The 
interfollicular region showed a mild increase in high endothelial venules, and large 
numbers of mature plasma cells (Fig. 3A, B). CD20+ B cells were confined to the follicles, 
and the CD3+ T cells resided mainly in the interfollicular regions. There was no 
immunoglobulin light chain restriction. The number of IgG4+ plasma cells was elevated 
(136 per HPF (Pt 1), 43 per HPF (Pt 2), and 94 per HPF (Pt 3)). The proportion of 
IgG4+/IgG+ plasma cells was 72.0% (Pt 1), 49.4% (Pt 2), and 53.4% (Pt 3); see Table 2, 
Fig. 3C, D. 
 
A bone marrow aspiration from one patient showed a normocellular marrow, with a 
normal myeloid to erythroid ratio, a normal number of megakaryocytes, and moderate 
plasmacytosis (12%). Discrete polyclonal plasmacytosis was found in the bone marrow 
aspiration. The mean number of IgG4+ plasma cells per HPF was 15, and the 
proportion of IgG4+/IgG+ plasma cells was 60.8 %.  
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Immunostaining of control skins 
Table 3 lists clinical features and the results of IgG4 and IgG immunostaining in 
controls. An increased proportion of IgG4+/IgG+ plasma cells was observed in 
pemphigus vulgaris and pemphigus foliaceus, ranging from 0 to 36.7% (mean 19.4%); in 
contrast there were none in discoid lupus erythematosus and morphea (vs pemphigus, 
P<.05). The inflammatory cells, including IgG4+ plasma cells, were more sparse in 
pemphigus than in cutaneous plasmacytosis. The lower number of IgG+ or IgG4+ 
plasma cells (pemphigus vs skin lesions of cutaneous plasmacytosis, P<.05), and the 





Since patients with sclerosing pancreatitis are recognized to have extrapancreatic 
lesions, and patients with extrapancreatic disease but with otherwise similar 
serological and histological features can have no pancreatic lesion, such lesions have 
been proposed as a manifestation of IgG4-related systemic disease.29,39 This disorder 
commonly presents with a high serum IgG4 level and/or abundant IgG4+ plasma cells 
in the tissues involved. Skin lesions have not been described in patients with typical 
IgG4-related systemic disease, such as sclerosing pancreatitis or sclerosing cholangitis.  
Our cases showed marked IgG4-positive plasma cell infiltration in the skin; this is not 
known as a feature of cutaneous plasmacytosis. All of our patients with cutaneous 
plasmacytosis had associated extracutaneous lesions (lymph node, lung, and bone 
marrow), in which numerous IgG4-positive cells were found by immunohistochemistry. 
Systemic involvement has also included a peri-ureteric retroperitoneal mass causing 
hydronephrosis,13 breast masses4, hepatomegaly10, and lymphoid interstitial 
pneumonia10 in association with cutaneous plasmacytosis. Histology shows diffuse 
lymphoplasmacytic infiltration within fibrous tissue.  
Concomitant lymphadenopathy is common in IgG4-related systemic disease. Lymph 
node histology in IgG4-related systemic disease that is associated with autoimmune 
pancreatitis, sclerosing cholangitis, sclerosing decryoadenitis or sclerosing sialadenitis 
can be categorized into three patterns: Castleman disease-like, follicular hyperplasia, 
and interfollicular expansion by immunoblasts and plasma cells.33 The lymph nodes in 
our cases showed reactive lymphoid follicles and marked distension of the interfollicular 
area by numerous plasma cells, and also a mild increase in thickened venules with a 
preserved nodal architecture. Histology of the lymph node in cutaneous plasmacytosis 
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was indistinguishable from lymph node lesions described in IgG4-related sclerosing 
disease; two of our cases fit best into the pattern of follicular hyperplasia, and one into 
the interfollicular expansion pattern specified in IgG4-related sclerosing disease.33 
Moreover, most patients are middle-aged to elderly ethnic Asians, with male 
predominance in both diseases.40 The clinicopathological similarities between cutaneous 
plasmacytosis and IgG4-related sclerosing disease indicate a relation with cutaneous 
plasmacytosis as a manifestation of IgG4-related disease.  
 
Allergic symptoms and atopic dermatitis are associated with high serum levels of 
specific IgG subclass antibodies to allergens, particularly IgG4. In pemphigus, 
autoantibodies belong mainly to the IgG4 and IgG1 subclasses. IgG1 antibodies against 
desmoglein are present with equal frequency in individuals with and without 
pemphigus, but IgG4 antibodies are present almost exclusively in patients with active 
disease.23,36 The present study finds increased IgG4+ plasma cells in patients with 
pemphigus group, although the significant increase in IgG4+ plasma cells (>40% 
IgG4+/IgG+ plasma cells) is likely to represent IgG4-related sclerosing disease, since all 
reactive lymph nodes not associated with IgG4-related systemic disease have a 
proportion below 30%.33  Abundant IgG4-bearing plasma cell infiltration, exceeding 
40% of IgG+ cells, is a characteristic histological finding for cutaneous plasmacytosis, 
and is not found in skin biopsies of control patients. The IgG4+/IgG+ plasma cell ratio in 
the lung biopsy specimen was lower than in skin or lymph node. This is probably 
because the specimen was small and unrepresentative of the whole lesion, although it 
might have been due to a different disease process. Involvement of the lung as a form of 
lymphoid interstitial pneumonia in cutaneous plasmacytosis has been recognized.10  
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These is also some evidence that interstitial pneumonia occurs during the course of 
autoimmune pancreatitis.31,41  Chest CT revealed diffuse ground-glass attenuation 
with honeycomb changes at the base of the lower lobe, or mild interstitial shadows. The 
histology in one case showed thickening of the lower lobe septum, with marked 
IgG4-positive plasma cells.31 We suspect that there is a close relation between these 
pulmonary changes and cutaneous plasmacytosis, because of elevated serum IgG4 and 
the infiltration of IgG4-positive plasma cells in the lung tissue.   
 
Cutaneous plasmacytosis could be a type of chronic allergic/hypersensitivity reaction, 
since allergic and atopic dermatitis are both associated with elevated IgE and IgG4. Our 
data were limited because of a lack of serum level of IgE and IgG4 in two of the three 
patients. None of our cases showed obliterative phlebitis or tissue fibrosis characteristic 
of IgG4-related sclerosing disease. Although our cases exhibited lymphadenopathy, bone 
marrow involvement, and possible evidence of lung infiltrates in one case, the evidence 
for cutaneous plasmacytosis as a skin lesion of an IgG4-related sclerosing disease was 
not convincing, because of the lack of pancreatic involvement. Activation of T helper 2 
(Th2) cells is believed to play a major role in allergic sensitization. The Th2 cytokines 
produce IL-4, IL-5 and IL-13, leading to the secretion of IgG4 and IgE by B cells. 
Allergic diseases are characterized by activation of the immune system and formation of 
IgE antibodies against specific allergens; IgG4 represents blocking antibody to 
IgE-coated mast cells.42 A parallel increase in the serum IgE concentration was found in 
20% of patients with sclerosing pancreatitis.21 IgG4-related sclerosing disease is an 
immune reaction mediated by Th2 cells and T regulatory cells.43, suggesting that 
cutaneous plasmacytosis and IgG4-related sclerosing disease have a common disease 
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process. Unknown environmental agents might trigger the production of IgG antibodies 
against unknown antigens, and trigger the subclass switching to IgG4 in B-cells. The 
geographical distribution of both cutaneous plasmacytosis and IgG4-related sclerosing 
disease has led to speculation that a HLA susceptibility gene is necessary for pathogenic 
activity of the disease. Another possibility is a primary infectious cause. 
Hyperproduction of IL-6 is also considered to be an important factor in the pathogenesis 
of cutaneous plasmacytosis. IL-6 induces B-cell proliferation and terminal 
differentiation, immunoglobulin secretion, and induces the acute inflammatory-phase 
response. An increase in IL-6 concentration has also been reported in cutaneous 
plasmacytosis.13,16,44 Our cases were all associated with elevated serum IL-6. Further 
studies are needed to determine the role of IgG4 in the pathogenesis of this disease.  
Since cutaneous plasmacytosis and IgG4-related sclerosing disease are both extremely 
rare, to learn more it is necessary to investigate a large series of patients and to provide 
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Fig. 1 Skin and lung findings in patient 1 
A: Diffuse red-brown papules on the chest and abdomen 
B: Chest CT showing ground-glass opacities and slight reticular shadows.  
C: Low-magnification photograph of cutaneous plasmacytosis showing dense 
perivascular and periadnexal infiltration of plasma cells in the deep dermis (HE, 
original magnification x20) 
D: Histological findings of lung biopsy specimen from the right middle lobe. Thickened 
alveolar septa due to lymphoplasmacytic infiltration (HE, x200) 
 
Fig. 2 Skin biopsy from patient 3 
A: Numerous infiltration of plasma cells in the dermis (x100).  
B, C: Immunostaining for IgG (B) and IgG4 (C) in the corresponding field. Increased 
IgG4+ cells are seen (x100). 
 
Fig. 3 Lymph node from patient 1  
A: Lymph node showing intact nodal architecture with reactive follicular hyperplasia 
(x200).  
B: The interfollicular zone is expanded and is densely populated by mature plasma cells 
accompanied by high endothelial venules (x200).  
C: Immunostaining for IgG. Numerous IgG+ cells are present between the follicles 
(x200). 
D: Immunostaining for IgG4. The number of IgG4+ cells is slightly higher than that of 
IgG4+ cells in the corresponding field. The IgG4+/IgG+ cell ratio exceeds 50% (x200). 
Table 1: Clinical features of patients with cutaneous plasmacytosis 
 



















Associated disease Treatment 
Follow-up 
(yr) 
1 54 M 4637 610 (13.2%) 46 6.9 
lymphadenopathy,  
interstitial lung disease 
PSL 15mg 1.5 




3 61 M 2624 NA 26.8 4.6 
lymphadenopathy,  
bone marrow plasmacytosis 
PSL 15mg 3 
Table 2: IgG4+/IgG+ plasma cell count and ratio in the various involved tissues of patients with cutaneous plasmacytosis 
 
Patient Location IgG4+/IgG+ plasma cells per HPF (%) 
1 Skin 53/153 (42.2) 
 Lymph node 136/189 (72.0) 
 Lung 14/91 (15.4) 
2 Skin 62/142 (43.7) 
 Lymph node 43/87 (49.4) 
3 Skin 72/124 (58.1) 
 Lymph node 94/176 (53.4) 
 Bone marrow 15/25 (60.8) 
Table 3: IgG4+/IgG+ plasma cell count and ratio of control  
A. Patients with pemphigus vulgaris 
 





IgG4+/IgG+ Plasma Cells per HPF (%) 
1 53 F 119 >150 6.6/18 (36.7%) 
2 73 F 105 2420 0/6 (0) 
3 47 F 33 29 1.6/11 (14.5%) 
4 63 M 43 2500 8.6/42 (20.5%) 
 
B. Patients with pemphigus foliaceus 
 





IgG4+/IgG+ Plasma Cells per HPF (%) 
5 77 F + - 11/53.7 (20.5%) 
6 64 F + - 10/65.7 (15.2%) 
7 21 F 240 - 5.6/19.6 (28.6%) 
 





Table 3 (cond’t) 
C. Patients with discoid lupus erythematosus 
 
Patient Age Gender IgG4+/IgG+ Plasma Cells per HPF (%) 
8 46 F 0/327 (0) 
9 32 F 0/13 (0) 
10 16 F 0/5 (0) 
11 11 F 0/5.3 (0) 
12 23 F 0/49 (0) 
 
D. Patients with morphea 
 
Patient Age Gender IgG4+/IgG+ Plasma Cells per HPF (%) 
13 51 M 0/3 (0) 
14 56 M 0/4 0) 
 



